Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: TDS, FVT

Dr. Stephen K. Klasko Named Mainstage Keynote Speaker at hc1's Precision Health Virtual Summit

INDIANAPOLIS, Oct. 29, 2020 /PRNewswire/ -- hc1, the leader in critical insight, analytics, and solutions for precision health that power high-value health care, announced today that Stephen K. Klasko, MD, MBA, will be the keynote speaker during its Precision Health Virtual Summit scheduled for Tuesday, Nov. 17 and Wednesday, Nov. 18. This special two-day summit hosted by hc1 in partnership with Becker's Healthcare will bring together healthcare leaders and experts to focus on the changes our care delivery system needs as it transitions from fee-for-service to value-based care reimbursement models.

Dr. Klasko is the President and Chief Executive Officer of Thomas Jefferson University and Jefferson Health. His session, "Beyond Genomics and Cell Therapy," will discuss health care's transition from costly and fragmented "sick care" to affordable, personalized and preventive care.

"The Precision Health Virtual Summit is a great opportunity for healthcare leaders to discuss how the COVID-19 pandemic, coupled with the connected care revolution, are transforming health care today for patients, payers and employers," said Dr. Klasko. "I'm excited to be partnering with hc1 and Becker's for this event."

Dr. Klasko was listed among the top physicians to know by Becker's Hospital Review and was named to Modern Healthcare's list of The Top 50 Most Influential Clinical Executives in 2020. He has authored and co-authored six books, including two in 2020: Unhealthcare: A Manifesto for Health Assurance with Hemant Tenaja and Patient No Longer: Why Healthcare Must Deliver the Care Experience That Consumers Want and Expect with Ryan Donohue.

"As one of the most influential healthcare visionaries, Dr. Klasko is the ideal keynote speaker to share a look into the future of healthcare at our Precision Health Virtual Summit," said Brad Bostic, Chairman and CEO of hc1. "It is hc1's goal to advance the promise of precision health, and those attending will walk away from Dr. Klasko's presentation with deep insights into the changes sweeping through the health care industry as value-based care models continue to expand."

Bostic, who will serve as the summit's opening keynote speaker, also announced that Amazon Web Services (AWS) and Quest Diagnostics, Inc. have joined as lead sponsors of the summit. AWS is a subsidiary of Amazon providing on-demand cloud computing platforms and APIs. Quest is the world's leading provider of diagnostic information services.

Joining Dr. Klasko and Bostic on the summit agenda are an esteemed group of presenters including some of America's top thought leaders in Precision Health:

Programming for the Precision Health Virtual Summit, which takes place November 17-18, will run each day from 12-2:30 p.m. EST. There is no cost to attend. To register for the Precision Health Virtual Summit, visit hc1.com/summit.

About hc1
hc1 is the leader in critical insight, analytics, and solutions for precision health.  The cloud-based hc1 Platform organizes volumes of live data, including lab results, genomics, and medications, to deliver solutions that ensure that the right patient gets the right test and the right prescription. Today, the hc1 Platform powers solutions that optimize diagnostic testing and prescribing for millions of patients nationally.  To learn more about hc1's proven approach to personalizing care while eliminating waste for thousands of health systems, diagnostic laboratories, and health plans, visit www.hc1.com and follow us on Twitter, Facebook, and LinkedIn.

Media Contact
Liz Goar
e: liz@npccs.com
c: (813) 503-2297



These press releases may also interest you

4 déc 2020
Today, Biocom California, the association representing the California life science industry, joined the Biotechnology Innovation Organization (BIO) and the California Life Sciences Association (CLSA) in filing a challenge against the Department of...

4 déc 2020
Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for use in the treatment of obesity in adolescents (12?17 years) with a body weight above 60 kg and an...

4 déc 2020
Today, the U.S. Food and Drug Administration authorized the first diagnostic test for at home collection of patient samples to detect both COVID-19 and influenza A and B (flu). The FDA authorized Quest Diagnostics RC COVID-19 +Flu RT-PCR Test for...

4 déc 2020
Samantha Castellanos-Santana was delivered at 30 weeks gestation and was born with an opening in her heart, a condition known as patent ductus arteriosus (PDA). On Nov. 25, 2020, Samantha became the first patient in West Central Florida to have this...

4 déc 2020
Regardless of their physical size, location or specimen load, Microbiology laboratories can significantly boost their efficiencies ? and subsequently cut labor costs ? by replacing manual processes with full automation, according to a new study...

4 déc 2020
Cerus Corporation today announced the oral presentation of a clinical study: "Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study," presented by Dr. Nina...

News published on 29 october 2020 at 09:10 and distributed by: